Joseph White, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 233 Magnolia St, Hazlehurst, MS 39083 Phone: 800-291-4020 Fax: 919-419-7247 |
Robert Walker, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 233 Magnolia St, Hazlehurst, MS 39083 Phone: 800-291-4020 Fax: 919-419-7247 |
Kenneth Whittington, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 233 Magnolia St, Hazlehurst, MS 39083 Phone: 800-291-4020 Fax: 919-419-7247 |
News Archive
ARIAD Pharmaceuticals, Inc. today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational BCR-ABL inhibitor, ponatinib, to the U.S. Food and Drug Administration (FDA).
With the health care community heavily focused on COVID-19 since the first quarter of 2020, there have been concerns that reporting of other diseases - and the resulting data that enables them to be more effectively treated and controlled - may have been impacted.
Business and healthcare leaders looking to fast-track preparedness for the H1N1 pandemic are gathering with infectious disease experts and Fortune 500 planners this month to determine how best to protect their employees and preserve their operations.
Researchers find that an experimental anticlotting pill Eliquis is more effective than standard drug, warfarin, at preventing strokes in people with a heart condition that puts them at high risk of blood clots and stroke. The new drug also known as apixaban, cut the risk of stroke by 21% compared with warfarin in people with atrial fibrillation (AF). It lowered the risk of dying by 11%.
› Verified 8 days ago